<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>Operator_BCSC1819_S12_C20_p381-404_3P</title>
		<link href="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="Operator_BCSC1819_S12_C20_p381-404_3P" lang="en-US">
		<div id="_idContainer021" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">CHAPTER</span><span class="cn-chap"> </span>20</p>
			<p class="chapter-title">Vitreoretinal Surgery and Intravitreal Injections</p>
			<p class="video-list-mid ParaOverride-1"><img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />&#9;<span class="italic">This chapter includes related videos, which can be accessed by scanning the QR codes provided in the text or &#173;going to </span><a href="http://www.aao.org/bcscvideo_section12"><span class="italic">www.aao.&#173;org/&#173;bcscvideo_&#173;section12</span></a><span class="italic">.&#173;</span></p>
			<p class="h1">Pars Plana Vitrectomy</p>
			<div id="Chapt20_Top1">
			<p class="body-text--no-indent-">Pars plana vitrectomy is typically used for removing vitreous opacities (vitreous hemorrhage), relieving vitreoret&#173;i&#173;nal traction, restoring the normal anatomical relationship of the ret&#173;ina and ret&#173;i&#173;nal pigment epithelium (RPE), and accessing the subret&#173;i&#173;nal space. This vitreoret&#173;i&#173;nal surgical technique involves a closed-&#173;system approach in which 3 ports are placed 3–4&#160;mm posterior to the surgical limbus. One port is typically dedicated to infusion of balanced salt solution into the vitreous cavity, by which intraocular pressure (IOP) can be maintained at a desired level. Epinephrine can be added to the infusion solution for mydriasis and to induce vasoconstriction to reduce intraoperative bleeding, but it may promote ischemia and increase inflammation. Dextrose is often added to infusions to reduce cataractogenesis for phakic diabetic patients. The remaining ports are used to access the vitreous cavity with tools such as a fiber-&#173;optic endoilluminator to visualize the posterior segment and other instruments to manipulate, dissect, or remove intraocular tissues, fluids, and objects.</p>
			<p class="body-text">Vitrectomy is performed using an operating microscope in conjunction with a contact lens or noncontact viewing system. Direct and indirect visualization are pos&#173;si&#173;ble; the latter requires the use of an inverting system to orient the image. The advantages of indirect visualization include a wider viewing &#173;angle, which enables visualization through media opacities and miotic pupils, as well as when the eye is filled with gas. Although direct viewing systems offer greater magnification and enhanced stereopsis, their field of view is smaller. Many vitreoret&#173;i&#173;nal surgeons use both types of viewing systems, selecting the type according to the pathology.</p>
			<p class="body-text">Vari&#173;ous instruments, visualization aids, and vitreous substitutes are used during vitreoret&#173;i&#173;nal surgery. Advanced instrumentation includes the high-&#173;speed vitreous cutter, intraocular forceps, endolaser probe, micro-&#173;pic, intraocular scissors, extrusion cannula, and fragmatome, among &#173;others. Examples of visualization aids include indocyanine green (ICG) or brilliant blue G (BBG) (not FDA-&#173;approved) dyes and triamcinolone suspension. &#173;These substances aid in the visualization of the internal limiting membrane (ILM) and, in the case of triamcinolone, also help identify the vitreous. Perfluorocarbon (PFC) liquids, which are heavier than &#173;water, can be used to temporarily stabilize the ret&#173;ina during dissection and facilitate anterior drainage of subret&#173;i&#173;nal fluid during ret&#173;i&#173;nal detachment repair. Tamponade of the ret&#173;ina can be achieved using air, gas, or silicone oil as a vitreous substitute. Commonly used gases include sulfur hex&#173;a&#173;fluor&#173;ide (SF<span class="subscript CharOverride-1">6</span>) and perfluoropropane (C<span class="subscript CharOverride-1">3</span>F<span class="subscript CharOverride-1">8</span>), which last approximately 2 and 8 weeks, respectively, at nonexpansile, isovolumic concentrations.</p>
			<p class="body-text">The development of smaller-&#173;gauge vitrectomy instrumentation has facilitated transconjunctival, sutureless vitrectomy techniques. With &#173;these systems, surgeons place 23-&#173;gauge, 25-&#173;gauge, or 27-&#173;gauge trocar cannulas to align conjunctival and scleral openings and to allow instrument insertions. &#173;These cannulas obviate the need for opening the conjunctiva, including cautery, and the wounds generally do not usually require suture closure when constructed with self-&#173;sealing architecture. Before small-&#173;gauge vitrectomy instrumentation, 20-&#173;gauge was the norm. The dia&#173;meter of 20-&#173;gauge sclerotomies is 1&#160;mm, compared to 0.7&#160;mm, 0.5&#160;mm, and 0.4&#160;mm for 23-&#173;gauge, 25-&#173;gauge, and 27-&#173;gauge instrumentation, respectively. Potential advantages of small-&#173;gauge vitrectomy include fewer intraoperative iatrogenic ret&#173;i&#173;nal tears, shortened operative time, increased postoperative patient comfort, faster visual recovery, and reduced conjunctival scarring.</p>
			<p class="reference--non-journal--first">Fujii GY, de Juan E Jr, Humayun MS, et&#160;al. Initial experience using the transconjunctival sutureless vitrectomy system for vitreoret&#173;i&#173;nal surgery. <span class="italic">Ophthalmology.</span> 2002;109(10):1814–1820.</p>
			</div>
			<p class="h1">Vitrectomy for Selected Macular Diseases</p>
			<div id="Chapt20_Top2">
			<p class="h2-h1">Macular Epiretinal Membranes</p>
			<p class="body-text--no-indent-">Epiret&#173;i&#173;nal membranes (ERMs) have a variable clinical course. &#173;There are generally 2 indications for surgery: (1) reduced visual acuity or (2) distortion causing dysfunction of binocularity. In general, epiret&#173;i&#173;nal membrane peel (Video 20-1) is advised if visual acuity is reduced to 20/40–20/60 or worse. Separately, dysfunction of binocularity that involves difficulty with fusion of 1 distorted and 1 normal-&#173;vision image is an indication for surgery, even if the patient’s visual acuity is still good (<span class="xref-figure">Fig&#160;20-1</span>).</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"> <span class="QR-code-number">VIDEO 20-1</span> Vitrectomy for epiret&#173;i&#173;nal membrane peel.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer002" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source">Courtesy of Colin&#160;A. McCannel, MD.</p>
			<p class="QR-code-text-last">Access all Section 12 videos at <a href="http://www.aao.org/bcscvideo_section12"><span class="Hyperlink">www.aao.org</span><span class="Hyperlink">/</span><span class="Hyperlink">bcscvideo_section12</span></a>.</p>
			<p class="body-text">&#173;After surgery, approximately two-&#173;thirds of patients achieve an improvement in visual acuity of 2 or more lines. Maximal improvement may take up to 6–12 months (<span class="xref-figure">Fig&#160;20-2</span>). Although improvement in patients with metamorphopsia is nearly universal, complete resolution usually does not occur.</p>
			<p class="h2">Vitreomacular Traction Diseases</p>
			<p class="h3-h2">Vitreomacular traction syndrome</p>
			<p class="body-text--no-indent-">Vitreomacular traction (VMT) syndrome is a distinct vitreoret&#173;i&#173;nal interface disorder that is differentiated clinically from typical ERM. Whereas ERM formation generally results from complete posterior vitreous detachment, VMT syndrome stems from anomalous, incomplete posterior vitreous separation at the macula. The fundus examination in VMT syndrome is often normal. The disorder may create focal elevation of the fovea (<span class="xref-figure">Fig&#160;20-3</span>) and, occasionally, a shallow ret&#173;i&#173;nal detachment. VMT syndrome is best diagnosed and differentiated from ERMs with the aid of optical coherence tomography (OCT); in eyes with this syndrome the hyaloid classically inserts onto a tractionally elevated macular ret&#173;ina, usually the fovea. Symptoms include decreased vision and distortion. VMT syndrome is often progressive and is associated with a greater loss of vision than are ERMs alone. Surgical treatment consists of a pars plana vitrectomy and peeling of the cortical vitreous from the surface of the ret&#173;ina. Intraoperative use of triamcinolone may aid visualization of the cortical vitreous. See <span class="xref-local">Chapter&#160;17</span> for further discussion of VMT syndrome.</p>
			<p class="reference--non-journal--first ParaOverride-2">Voo I, Mavrofrides EC, Puliafito CA. Clinical applications of optical coherence tomography for the diagnosis and management of macular diseases. <span class="italic">Ophthalmol Clin North Am.</span> 2004;<br />17(1):21–31.</p>
			<p class="h3 ParaOverride-3">Idiopathic macular holes</p>
			<p class="body-text--no-indent-">Vitrectomy surgery is not generally recommended for stage 1 macular holes &#173;because approximately 50% of them &#173;will resolve spontaneously. It is definitely indicated for all recent full-&#173;thickness macular holes (stages 2, 3, and 4). Early intervention for full-thickness macular holes is important; shorter time intervals between the development and the closure of macular holes have been associated with improved anatomical and functional outcomes.</p>
			<p class="body-text">Surgery for full-&#173;thickness macular holes typically consists of a pars plana vitrectomy, separation and removal of the posterior cortical vitreous, optional removal of the ILM, and use of an intraocular air or gas tamponade (Video 20-2). Vari&#173;ous studies have demonstrated that ILM peeling improves the rate of hole closure, particularly for larger stage 3 or 4 holes, and reduces reopening rates. ILM inverted flaps is a newer surgical technique used to repair macular holes, but &#173;there is no consensus on &#173;whether this technique improves visual acuity in patients with large macular holes (Video 20-3). The intraoperative use of dyes (eg, ICG, trypan blue, BBG) or other visualization techniques (eg, triamcinolone) to aid in peeling the ILM is widely practiced, despite potential toxicity. Duration of face-&#173;down positioning ranges from a few hours to 2 or more weeks. Since the early 2000s, most studies have reported macular hole closure at rates higher than 90% (<span class="xref-figure">Fig&#160;20-4</span>). &#173;After successful closure, it is uncommon for the hole to reopen; however, this may occur if severe cystoid macular edema or ERM develop.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer003" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"> <span class="QR-code-number">VIDEO 20-2</span> Vitrectomy for macular hole repair with ILM peeling.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer004" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source">Courtesy of Colin&#160;A. McCannel, MD.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer005" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first ParaOverride-4"> <span class="QR-code-number">VIDEO 20-3</span> Inverted ILM flap for macular hole closure.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer006" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source">Courtesy of María H. Berrocal, MD.</p>
			<p class="reference--journal--first ParaOverride-5">Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. Results of a pi&#173;lot study. <span class="italic">Arch Ophthalmol.</span> 1991;109(5):654–659.</p>
			<p class="reference--journal--last">Kumagai K, Furukawa M, Ogino N, Uemura A, Demizu S, Larson&#160;E. Vitreous surgery with and without internal limiting membrane peeling for macular hole repair. <span class="italic">Ret&#173;i&#173;na.</span> 2004;24(5):721–727.</p>
			<p class="h2 ParaOverride-6">Submacular Hemorrhage</p>
			<p class="body-text--no-indent-">Vitrectomy for submacular hemorrhage remains unproven and controversial. The clinical course of submacular hemorrhages can vary. Patients with neovascular age-&#173;related macular degeneration (AMD) and larger submacular hemorrhages generally have poor visual outcomes. For removal of thick submacular hemorrhages, pars plana vitrectomy techniques can be considered. The surgery involves pneumatic displacement of subret&#173;i&#173;nal blood away from the macular center without attempting to remove the hemorrhage. This technique can be performed with a vitrectomy, subret&#173;i&#173;nal injection of tissue plasminogen activator (tPA) via a 39-&#173;gauge to 41-&#173;gauge cannula, and partial air–&#173;fluid exchange. Postoperative face-&#173;down positioning can result in substantial inferior extramacular displacement of the blood (<span class="xref-figure">Fig&#160;20-5</span>). Intravitreal injection of expansile gas (eg, SF<span class="subscript CharOverride-1">6</span> or C<span class="subscript CharOverride-1">3</span>F<span class="subscript CharOverride-1">8</span>) and face-&#173;down positioning, with or without adjunctive intravitreal tPA administration, has also been performed in an office setting. Resolution of submacular hemorrhage with improvement of visual acuity can be achieved with administration of anti-&#173;VEGF agents alone, particularly if the blood is of mild thickness. Following treatment of the submacular hemorrhage, most patients require chronic treatment for the exudative AMD, usually with anti-&#173;VEGF injections.</p>
			</div>
			<p class="h1">Vitrectomy for Vitreous Opacities</p>
			<div id="Chapt20_Top3">
			<p class="body-text--no-indent-">Surgery to remove vitreous opacities or symptomatic floaters is becoming more common; however, proper case se&#173;lection is necessary. Surgery and its pos&#173;si&#173;ble complications are not a good match in many cases. However, if the vitreous opacities affect reading, driving, or visual per&#173;for&#173;mance in general, vitrectomy surgery may be an appropriate solution. YAG &#173;laser photodisruption can be used as an alternative to surgical removal of floaters. However, &#173;there is very &#173;little scientific lit&#173;er&#173;a&#173;ture assessing the efficacy and complications of this technique, resulting in limited adoption.</p>
			</div>
			<p class="h1">Vitrectomy for Complications of Diabetic Retinopathy</p>
			<div id="Chapt20_Top4">
			<p class="body-text--no-indent-">Advances in vitreoret&#173;i&#173;nal surgical techniques have facilitated earlier surgical intervention in patients with diabetic retinopathy, with reduced surgical morbidity and decreased surgical duration. &#173;These advances include the routine use of intraocular endolasers, widefield noncontact viewing systems, smaller-&#173;gauge surgical instrumentation, bimanual surgical techniques, and perioperative anti-&#173;VEGF injections. In addition, the use of anti-&#173;VEGF agents prior to vitrectomy for proliferative diabetic retinopathy (PDR) reduces intraoperative bleeding as well as surgical duration, the incidence of intraoperative ret&#173;i&#173;nal breaks, and the number of endodiathermy applications. Pre-&#173;operative use of anti-&#173;VEGF agents can help reduce intraoperative bleeding but can lead to traction ret&#173;i&#173;nal detachment if surgery is significantly delayed following the injection.</p>
			<p class="h2">Vitreous Hemorrhage</p>
			<p class="body-text--no-indent-">Vitreous hemorrhage is a common complication in patients with PDR. Vitrectomy is indicated when a vitreous hemorrhage fails to clear spontaneously &#173;after approximately 4 weeks to 3 months; the timing of the surgery is determined by the surgeon’s preference and the patient’s visual requirements. Pos&#173;si&#173;ble indications for more prompt intervention include monocularity, bilateral vitreous hemorrhages or ultrasonic evidence of a ret&#173;i&#173;nal tear, under&#173;lying rhegmatogenous ret&#173;i&#173;nal detachment, or tractional ret&#173;i&#173;nal detachment that threatens the macula. In the absence of ophthalmoscopic visualization, serial ultrasonography helps the clinician assess the anatomical condition of the ret&#173;ina. If surgery is indicated, treatment involves a pars plana vitrectomy with removal of vitreous hemorrhage (Video&#160;20-4) and release of the hyaloid from fronds of ret&#173;i&#173;nal neovascularization. Vitreoret&#173;i&#173;nal traction at the optic nerve head and along the arcade vessels, if pres&#173;ent, is addressed at the time of surgery, along with any macular ERMs. Complete panret&#173;i&#173;nal photocoagulation and hemostasis should generally be achieved during the procedure. To prevent bleeding or rebleeding, the eye may be filled with air or a short-&#173;acting gas to tamponade pos&#173;si&#173;ble bleeding sites.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer007" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,/9j/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAAlgAAAAEAAQCWAAAAAQAB/+4AJkFkb2JlAGQAAAAAAQMAEAMDBgkAAAAAAAAAAAAAAAAFAAJJRP/bAIQAAgICAgICAgICAgMCAgIDBAMDAwMEBQQEBAQEBQUFBQUFBQUFBQcICAgHBQkKCgoKCQwMDAwMDAwMDAwMDAwMDAEDAgIDAwMHBQUHDQsJCw0PDQ0NDQ8PDAwMDAwPDwwMDAwMDA8MDg4ODg4MERERERERERERERERERERERERERER/8IAEQgARwBHAwERAAIRAQMRAf/EAKYAAAMBAQEBAQAAAAAAAAAAAAYHCAkFBAIDAQEAAAAAAAAAAAAAAAAAAAAAEAADAAMAAgIDAQAAAAAAAAAEBQYCAwcBCGATEhUWFxEAAQQBAwMDBAMAAQUAAAAAAwECBAUGERITACEUIhUHMUEyI1FhFkKRUiQ0FxIBAAAAAAAAAAAAAAAAAAAAYBMBAQEBAQEBAAMAAAAAAAAAAREAITFBUWBhcf/aAAwDAQACEAMQAAAA2yFcGh8C0C05p+IzRUmUArSzSdRhgsc81bPOZkCbHcHAsTsDzK6GGYgAQHg7ReHiD40HPOZJCsL4JGKaJdH2arAeZpinKTEwKwch5jUQOzOMnY7geA6I0cppiFxk8OIjgbYriugJNIRyirFSCxyC2CGi3xvn/9oACAECAAEFAfiP/9oACAEDAAEFAfiP/9oACAEBAAEFAaiqWSIX+qotZqK6T0ihl0OOVYaO3c++3f0tNoSp+tSTzRq6wiK2pq9Y+QdXyMHAgYU2ZJ8ryGbAUx39zERjWc1Us0w21KaJo81MQXQEc5LKBje3oiKWAcSPTzetU7GkSEMB2X4R8xEu8U++TYKlBJc6w1S6CskZtcgw5P0V89n5nSZnnAQmwlQLg3R4gzaXc0LA6EpnMud63koFPToq/cNO7MPX/vdFnKwk2o4xg45U8g1asWZ42rUadsnrSPhdRKMFDU+ZlRqTkPp0Bt4g+3q2DiE6tqUrCkaCl9eS4ZneTGxE5epWdN54390Lns1VbNhuc+BqTZnwLpwwRSN9YjPdVd0NtRNZXWEumElpAf2neYaqQQ830tQLHjXPIthcgKSVxzrOBZK+BuDqUml55bbfASvowUO1S9LSQWmmUQsxRDsLsAauAuBJyf0O+QWKKfoQy+dyIZi2J4KMuBifWr9E45Z687Z1YpjFQVny31vKpRkcduCDExDw/9oACAECAgY/ASP/2gAIAQMCBj8BI//aAAgBAQEGPwGJNsxTJCT5gq+MCBHJKOWQZHKxjRDRV+jF6qYU+lyOnW7nhrYhrColRwOkyF0GNSPZomunRL2mjWUysSD54ipCMnkM3nYowIrdXlRQLqxO/dv/AHJ07yrwCykmuq2QxLySi2DBjJ4Ywt1c42hWaMTv6k6nhtrGRirq4zYxlv4xa5vkKxpeFqnRqK9GPa5UT/i5F+/RMg9nvz1LDPHzAqpJNwWC5vKaiM1UCt/En0XohYKWXOyZEgNhlgmHLIWaBJYeMLmo5yeP+1V+zEVy9upzK2jyW3FXTZEAsiDTyjgU8UjhGawjWaLo9qp26mZDXRp740F8sRYr4pGTUNBc9hg+Mqb9+4aojdO69YjZxaixumU2TwpsmPVRny5KAaOQxz2iZ3XRXpr1QVFZBzW8dYZrQWsiTbY5JrI0ONWrJ5XuK85078/9fTqo+NcwaX43p5rqcEUQZSPu50Q9jL8ME2O9jEI5hXEVHjaPhR6Oe0uqJ1P+Sa+0m5FAyqjf5No+H7RFqK794a9Iby+W0ZBSmq+QQm9BhXkVuid8PzvMLaI+wgza1f8ARkgkbLjRH36xVVlp5PiueNG7l1jfhov36nZFjo4t3i0CSUJJW0hoJLCed1a6yO1hW6S5bTpHeHciNE5JaJtVBdVz4woXwxX1l2y8hxKaOa4lSmxJn+aktkTCSRMRFNKcNEQX4Lu76d40Syrc3oj4vlWRzWe2Y3JsY0wE+0WSJ4zsOBNNjE0XRfr/ANcivZ1HbQvIu8guRVx4j2WL45psmQJqRV9W97FTa376p1Poq6JIlXtjIAOoWOpmIGajtwylILTYxqI7Vz/T9l+qdTshPkD86HTjBEZIpo5QAi2hHlUcAKDMdgHh26uMZCMFvapmLuTqNl1jQ2EOTbHHOJWT606304lO5Hy5BZqo0Y1rxqwoTsjtC7f62P43J18f2WC/EB7Yr0fFSJNmyJH+bn6PdFr5ABcCCCEhGyHrIb62kVqqiaaRLikxOuyZ2L10q9t/ADYDFLtwnlcNbGiumlZHKwoGuVHNfyNcitYjXJ1TvwXNg4rnMfIJthNh28uNWgjXEhCG/dVzW8kldHtg6jc1qL+xGpt06tMar4tp8Wrb2IreZmWWvCCpfOa1CyoMaNOigQwnmc9GsYbcuiF3K1q622QZHl5MuhZFkBPd8nSd7FAp21vkxwmhCe9WuEjlQOm9d6O366p1YVdXJgxKn26xjmsDtkjrHvc0qSJjOeUpFiucqva5D6Kzu1+mi9HkYxSMyHIZpWQ4EEhwx2EKXX8nFMDXRrV7NXd/WmumWYnYAk1DvM3wsiu5KvcKohNVIp1DRGIYrmKYi+SgnAf9CEdtREva2/ySLAHa0yVt340n3lB1ZkO2RZlVrppWmeEy8bY/62KNFlNY1U3U58YtqagpsN8rJ7FK+TaHkTpTg8STo5ZDzCY79LEjhmuarjN2vGo3JuEuJYLe4NjU+IO3LIspLObUpSMtZZIQpJpKrMgjUItotEf6hoz8+olO/A7WqxHG50mXfMnQI4msx+aU1fCfFJNRtgRqySsK9yryb1eiLtRESzl2ceZmGGfIFtIo6XG5UGaQwZZ0M6FNc6aFhHR/CCqucEjl2PRV9SLpGfQYTc12I1WQnZkRGvSwpWHrIU+rkLAh80meRj5Rkf6xqvZF0TTp2KLMapP8KWs8rx5SN1dXuFyeOoPJ0767ePf9tuvbpLwV17ESJZRtpmRAyzk3b2qKP5AyCGRyL2I5NGpr379OqbENvYkjVVdWEZyXE9yuAspbmOItM4ono1CA7NVQ9/7XqID3m3p7vzJ0b3AFKOwFU+XtHxPH4plkNsBtQTGERyjcN2iN3arjMKopp+YZjDrghqxuhWMSLPmCkFLDBbsCNsZjudfUknu1ujnenTqkBfpksP5Ymy4qWMUK5Ak1YLLYj5oxIxeB0dkJF28eqoqKqd+qC7L8j49i5Y9i4tnIs193sCgMd0CDHLDI4zeNkVQuVj2ekqKQiNej3dZPbCvbfJD1mUx4VoOL5iWFfXLLRdRCRePiMBGkR8RN6I5G68SvTp8H4mAVMYsolpHyKfZzb2vra96T45Ih+WcUJFlbmI0jRr3cq6+nXqwrK69e7L+OwjmuJQCIz3tVI00pgJDdOJJHqY1rePbojE26dSIdLRNv8g8sBKoT1i7Aymbladw5bmjJtbu9Gjtdfx/jDp+K5GLH6G2rMgnRLDw59cyoHYe3oLYGljxzM04XKxZDFR2i792iIk+5kUs3KaU0ih89Wkr5EOYd0gzmyBgc7zGubvTxXbUXl3bu2nToceG3/wCoZRaNmZg7IzOkRIjJiDj1xRx6gqjYhSt4+7ORq9ybRbV6x5mRxZOTQckspFfGzStkOKaPoZUbNikmEWXHQMl6jIwiNjvGP8H6vV2GTD0g5+Sy8itoWQHRszhlkVZsaLNeYukV6KfjORBLt+rUbt9PV7UfI/yRYUF7oyynuhqgASpNU4SxZsKVAA0Hi+3A4XjIv5u02b9NL2Zk80VxQWY7WzqKmTKQdQsKRYMkxbJ0SjIKSRNm1r2Fa4/IRr9m1pHNdlqw0Qv+GLaeL5EpU1bXuLx+QpvI+2m/k3/fdr36rwzXTVRbWMoQVgt8+QZEIrQxDcgfHIv2Mj27URU1TXr5YXMK+2JjcS1p4EmG6O6mtEA9LBCwWmrVk+ajE02NKRo13Lq5qaKtZRTY1OkXK310isLjhy+8HjyCqCndGO6JFe8tdIGUu0pGI5z9uqJqvVl8k5LByqbTBNxFyqtsFqLOfVKqMjOPHgTHOkSUlOehXHI1Wi2u3O0RvWK1uFWr42E0kFlSGNaRpPj5AW6lmSUA03iO8jQJKVzBlbsUuqdvy6xu6YkS0xzHcgJOsKKGEXtsZPKIGNw67eMbhKMTwDHt5Fe9dXK5V+WFiYQOslRT18usobYDbGBFgFnQll14nSh9uYxFMgkGiJ+aJq3XqdfYZjDPjX5bs6sIq0lxW6VIZSvAM7YowiMiP2K5OThbqmuumqp1bU8BIiXYYFtVl89iOqfcxoYJeIT2uH4HNrxsRmzi0RGadusRq41vY0o7rJ4UKSeqkviSVA4ch7mNKPumqsTXqguK+bm1E+uzXH6k8a2yOVZxpkayWTyscIgAJ24E/n69UM+4xDFLqupVAFUwhzYF+xwJBStkwZL440E0XKjnC36a/wDJNdUz7GKRiQ6STLTFHo8ja6YCWJwpSPnx475IiHsEkNiI/l9XZr1RqdYn8PipWguraWCtqraPcu8VFgSW3RJw4/A1GcfNseTfu/WuiLonU/EMzts7uZN7NDKiSOERa3jrbZkmS+FHJYd1JJiF/au1ytcjlb/OSTfbageUYweDcWkiRLJDjv2qC3r3iisjF5JLa1GRXGe5qt1exNzO/QM3yOltauoXHr2TWEhWRLC7iml3VfGI+MZ4Y3C1vPsYjVX9Wrfp2Ww+Oo04wvAqbDCH2EiPtVSxBlrXymgQq+hXN3NTf3T79VcG/nlrdtmA1eaPMdBP5zEfxIEjHscrtFd6U+vVBOvsmu5KwraKesFcXskgH2LFVY6NGYu179ddrfv/AB0EVdc1T60bJu1W3LCDVkf9ttq7nXVHie1sz+RoxCelE6fGq7jHEoKV0Y1s6LdB4ZDUO10dtsRsjQrObTahV03dk6ofe8qC3D+SQ6jbJyZzK1HOeqmSErpKD/L67V7dYTXslxpnt6OTGTTpTZMh+scn/qlI5XE/8dXfjr6P66tJOd5TDZlMh7STG22S8Mpu5jVGjhlktc1qD27E0/HTTt1SVFXOGI4qIUeqkwZm2etQJ0ZUcA7H8iiVWC3ORdF7ar36Mxpzn5jlOqyCOKrVK9Xq1quVdGJro1v0ROydf//aAAgBAgMBPxD+I//aAAgBAwMBPxD+I//aAAgBAQMBPxBxhwWEX1CyAdw1Ns8xtdqKzm4432AKQHFPh6d9o1QN05hSP3dE3opjU3pTwxgCN3sKe68T5DcLhedtCKk5JkMm2m/dHNoqcwBNdwUGySVAPcQf1Bc+nynhha/+C0rgqr/p8POIPlLijg5BLg/SAXczPkMQBB41xJfLR7iVjO6NhkQZjd0qFcjsRNuD/vBnxPWHzYECvXzJSTl4hRyB1Ae5megAjWLtC06BjbBZcN3keISLSRRT4ojS4B4FoeJ1Qelc0DctUVxMH5Cdm1paI3ZakRAVWT5rS2ZJGQ3UBiqlDBLkiT8URyFy4+OK7ovGhPURtJ2OI3pkgsgRmrFyptG4eYt/m/LSHBqgrhV+5e+/XKvReiz5KI3pA6Ichdf7Q4FhloNy4bevBnWLQA5WRMb3Yo8ELtMVGasA8iH6c454/nj36TaghA4Iwxv1z4Gkvvk9F2OogpmshFgR5FkmpHg+KATK2pu1evhv9F4hx/8AsuGEsTpgY9JZ/kcErPdpGk6oZ9oS5Zz99Fu2QqtIPAtcBuxIV2fR2Ipcc0tUVXuoABeY0+2Btz2VJjsjJhiviyn+4ROHdU4qGZis96YRCOJWiC62/uOAZ1JYRhpY0IOiP96TaDI4QMKHMUZA7sv4PxzwvZE1st41R4FeCSX0QyEwc0xV39om6OFpmUfcPeKS7UnKByM9ngFwjBkuioWlCmPgWCDEED21/wBpK6y1CH/J3ej2Ewzt1higHBCnQgTIbRNr9/eCKj03B+08KIwSPw8+pQPotHoACivTg57JY5kD1HqeSakl60aaI6AlV/6Fj4kGtKCaJP7DXSHKCGLZNKQJN+EsO5gMrC21FNGUxEe4A52Z9vDIii8ZjdvOW3qeAL1Fmg/EtFw62MmWN/ZQW5EvrzgPmVFKaNEZKC3wzCp+j5pXwapT+buiVHIjGAQB+JgwzTV4Y/KXsmiiW1JTRsjiOBv/2Q==" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto"> <span class="QR-code-number">VIDEO 20-4</span> Vitrectomy for vitreous hemorrhage.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source-recto">Courtesy of Colin&#160;A. McCannel, MD.</p>
			<p class="h2">Diabetic Tractional Ret&#173;i&#173;nal Detachment</p>
			<p class="body-text--no-indent-">Tractional ret&#173;i&#173;nal detachment (TRD) occurs when the hyaloid contracts but fronds of neovascular ingrowth prevent it from separating from the ret&#173;i&#173;nal interface. The tractional forces are transmitted to full-&#173;thickness ret&#173;ina and, in the absence of a ret&#173;i&#173;nal break, cause schisis and/or detachment of the under&#173;lying ret&#173;ina from its corresponding RPE (<span class="xref-figure">Fig&#160;20-</span><span class="xref-figure">6</span>). Vitrectomy is indicated when progression of a TRD threatens or involves the macula. In certain complex cases, spontaneous breaks can also occur in an atrophic ret&#173;ina &#173;under traction, resulting in combined traction and rhegmatogenous detachments; this variety of TRD is also a strong indication for earlier surgical intervention. Although panret&#173;i&#173;nal photocoagulation should precede vitrectomy whenever pos&#173;si&#173;ble, it can be more difficult to accomplish in the presence of vitreous hemorrhage. A preoperative adjunctive intravitreal injection of an anti-&#173;VEGF agent may induce regression of neovascularization, facilitating dissection and minimizing intraoperative bleeding.</p>
			<p class="body-text">Vitrectomy for TRD is performed to relieve vitreoret&#173;i&#173;nal traction that interferes with ret&#173;i&#173;nal reattachment. In this procedure, the cortical vitreous and posterior hyaloid are removed from the ret&#173;i&#173;nal surface, particularly in areas of ret&#173;i&#173;nal neovascularization. Point adhesions of cortical vitreous to surface ret&#173;i&#173;nal neovascularization can be relieved by unimanual or bimanual techniques using vari&#173;ous instruments, including scissors or the vitrectomy cutter. Surgical approaches to fibrovascular tissue include segmentation and delamination. In segmentation, bands of fibrovascular tissue causing traction are cut, but the epiret&#173;i&#173;nal proliferations are not completely removed. In delamination, the epiret&#173;i&#173;nal proliferations are completely, or nearly completely, dissected off the ret&#173;i&#173;nal surface to relieve the traction.</p>
			<p class="body-text">&#173;After tractional membranes are removed, diathermy may be used to treat fibrovascular tufts and achieve hemostasis, and supplementary &#173;laser treatment may be used in the periphery to reduce ischemia.</p>
			<p class="reference--non-journal--single">Brunner S, &#173;Binder&#160;S. Surgery for proliferative diabetic retinopathy. In: Schachat AP, Wilkinson CP, Hinton DR, Sadda SR, Wiedemann P, eds. <span class="italic">Ryan’s</span> <span class="italic">Ret&#173;i&#173;na.</span> Vol 3. 6th&#160;ed. Philadelphia: Elsevier/Saunders; 2018.</p>
			<p class="h2 ParaOverride-8">Diabetic Macular Edema</p>
			<p class="body-text--no-indent-">The current mainstays of treatment for diabetic macular edema are intravitreal anti-&#173;VEGF, corticosteroid pharmacotherapy, and photocoagulation (for more information regarding pharmacologic agents, please see Chapter&#160;5 of this volume). However, vitrectomy with membrane peeling may be considered for recalcitrant cases in which the posterior hyaloid or epiret&#173;i&#173;nal membrane is taut. In &#173;these instances, the surgeon performs a pars plana vitrectomy with mechanical release of a taut hyaloid, peeling of epiret&#173;i&#173;nal membrane, and stripping of the ILM as necessary.</p>
			</div>
			<p class="h1 ParaOverride-9">Vitrectomy for Posterior Segment Complications <br />of Anterior Segment Surgery</p>
			<div id="Chapt20_Top5">
			<p class="h2-h1">Postoperative Endophthalmitis</p>
			<p class="body-text--no-indent-">Postoperative endophthalmitis is classified based on the time of onset in the eye; <span class="italic">acute onset</span> occurs within 6 weeks following surgery, and <span class="italic">delayed onset</span> occurs more than 6 weeks following surgery. A specific subtype of endophthalmitis that occurs <span class="italic">following filtering bleb surgery</span> has a markedly dif&#173;fer&#173;ent spectrum of causative organisms.</p>
			<p class="h3">Acute-&#173;onset postoperative endophthalmitis</p>
			<p class="body-text--no-indent-">Clinical features of acute-&#173;onset postoperative endophthalmitis include the following signs: intraocular inflammation, often with hypopyon, conjunctival vascular congestion, and corneal and eyelid edema; symptoms include pain and loss of vision. Common causative organisms are coagulase-&#173;negative <span class="italic">Staphylococcus</span> species, <span class="italic">Staphylococcus aureus, Streptococcus</span> species, and gram-&#173;negative organisms. Monitoring includes obtaining intraocular cultures. An anterior chamber specimen is typically obtained by using a 30-&#173;gauge needle on a tuberculin syringe. A vitreous specimen can be obtained &#173;either by needle tap or by using a vitrectomy instrument. A needle tap of the vitreous is typically accomplished using a 25-&#173;gauge, 1-&#173;inch needle on a 3-&#173;mL syringe (to provide greater vacuum) introduced through the pars plana and directed &#173;toward the midvitreous cavity. Vitreous specimens are more likely to yield a positive culture result than are si&#173;mul&#173;ta&#173;neously obtained aqueous specimens. Management includes administering intravitreal antibiotics; the antibiotics commonly used include ceftazidime and vancomycin. Ceftazidime has largely replaced amikacin or gentamicin in clinical practice &#173;because of concerns of potential aminoglycoside toxicity. Intravitreal dexamethasone may reduce posttreatment inflammation, but its role in endophthalmitis management remains controversial.</p>
			<p class="body-text">The use of vitrectomy for acute-&#173;onset postoperative endophthalmitis is guided by the results of the Endophthalmitis Vitrectomy Study (EVS; <span class="xref-sidebar">Clinical Trial 20-1</span>). In the EVS, patients &#173;were randomly assigned to undergo &#173;either vitrectomy or vitreous tap/biopsy. Both groups received intravitreal and subconjunctival antibiotics (vancomycin and amikacin). The EVS concluded that vitrectomy surgery was indicated in patients with acute-&#173;onset (within 6 weeks of cataract extraction) postoperative endophthalmitis with light perception vision (<span class="xref-figure">Fig&#160;20-7</span>). Patients with hand motions visual acuity or better had equivalent outcomes in both treatment groups.</p>
			<p class="reference--journal--single">Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. <span class="italic">Arch Ophthalmol.</span> 1995;113(12):1479–1496.</p>
			<p class="h3">Chronic (delayed-&#173;onset) endophthalmitis</p>
			<p class="body-text--no-indent-">Chronic endophthalmitis has a progressive or indolent course over months or years. Common causative organisms are <span class="italic">Propionibacterium acnes</span>, coagulase-&#173;negative <span class="italic">Staphylococcus</span> spp, and fungi. Endophthalmitis caused by <span class="italic">P acnes</span> characteristically induces a peripheral white plaque within the capsular bag and an associated chronic granulomatous inflammation. An injection of antibiotics into the capsular bag or vitreous cavity does not usually eliminate the infection; instead, the preferred treatment is pars plana vitrectomy, partial capsulectomy with selective removal of intracapsular white plaque, and injection of 1&#160;mg intravitreal vancomycin, adjacent to or inside the capsular bag. If the condition recurs &#173;after vitrectomy, removal of the entire capsular bag, with removal or exchange of the intraocular lens (IOL), should be considered (<span class="xref-figure">Fig&#160;20-8</span>).</p>
			<p class="reference--journal--single">Clark WL, Kaiser PK, Flynn HW Jr, Belfort A, Miller D, Meisler DM. Treatment strategies and visual acuity outcomes in chronic postoperative <span class="italic">Propionibacterium acnes</span> endophthalmitis. <span class="italic">Ophthalmology.</span> 1999;106(9):1665–1670.</p>
			<p class="h3 ParaOverride-10">Endophthalmitis associated with conjunctival filtering blebs</p>
			<p class="body-text--no-indent-">Except for the additional sign of a purulent bleb, the clinical features of conjunctival filtering bleb-&#173;associated endophthalmitis are similar to &#173;those of acute-&#173;onset postoperative endophthalmitis. &#173;These features include conjunctival vascular congestion and noticeable intraocular inflammation, often with hypopyon (occurring months or years &#173;after glaucoma filtering surgery). The initial infection may involve the bleb only <span class="italic">(blebitis),</span> without anterior chamber or vitreous involvement. Blebitis without endophthalmitis can be treated with frequent applications of topical and subconjunctival antibiotics and close follow-up. However, if blebitis progresses to bleb-&#173;associated endophthalmitis, patients are treated with intravitreal antibiotics with or without vitrectomy. Bleb-&#173;associated endophthalmitis typically occurs months to years &#173;after surgery, and causative organisms include <span class="italic">Streptococcus</span> spp, <span class="italic">H</span><span class="italic">a</span><span class="italic">emophilus</span> species, and other gram-&#173;positive organisms. The recommended intravitreal antibiotics are similar to &#173;those used in acute-&#173;onset postoperative endophthalmitis. However, the most common causative organisms in bleb-&#173;associated endophthalmitis (ie, <span class="italic">Streptococcus</span> or <span class="italic">Haemophilus</span> spp) are more virulent than the most frequently encountered organisms in endophthalmitis that occurs &#173;after other intraocular surgeries (such as cataract surgery). Even with prompt treatment, the visual outcomes in bleb-&#173;associated endophthalmitis are generally worse than for acute-&#173;onset endophthalmitis &#173;after cataract surgery (<span class="xref-figure">Fig&#160;20-9</span>). Management of filtering bleb-&#173;associated endophthalmitis is similar to acute-&#173;onset post&#173;operative endophthalmitis; however, vitrectomy may be more commonly considered.</p>
			<p class="h2 ParaOverride-11">Retained Lens Fragments &#173;After Phacoemulsification</p>
			<p class="body-text--no-indent-">The incidence of posteriorly displaced, or retained, lens fragments ranges from 0.3%–1.1% in reported series. Retained lens fragments may cause severe intraocular inflammation and secondary glaucoma. Nuclear fragments usually continue to cause chronic intraocular inflammation, whereas cortical remnants usually spontaneously reabsorb (<span class="xref-table">&#173;Table&#160;20-1</span>).</p>
			<p class="body-text">Indications for vitrectomy include secondary glaucoma, lens-&#173;induced uveitis, and the presence of large nuclear fragments. In the 4 largest reported series, 52% of patients with retained lens fragments had an IOP of at least 30&#160;mm Hg before vitrectomy. Removal of the lens fragments reduced this incidence by 50% or more in &#173;these series. Pars plana vitrectomy, with or without use of a fragmatome, is the preferred approach to remove harder pieces of the lens nucleus (Video 20-5). Following lens fragment removal, the ret&#173;i&#173;nal periphery should be examined for the presence of ret&#173;i&#173;nal tears or ret&#173;i&#173;nal detachment.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer009" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"> <span class="QR-code-number">VIDEO 20-5</span> Vitrectomy for removal of retained lens fragment.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer010" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source">Courtesy of Colin&#160;A. McCannel, MD.</p>
			<p class="body-text">Reported studies with long-&#173;term follow-up have found that ret&#173;i&#173;nal detachment occurs in about 15% of eyes with retained lens fragments. Aggressive attempts to retrieve posterior lens fragments using a limbal approach are sometimes complicated by ret&#173;i&#173;nal detachments caused by &#173;giant ret&#173;i&#173;nal tears. &#173;Giant ret&#173;i&#173;nal tears are more commonly found 180° away from the incision used for cataract surgery.</p>
			<p class="reference--journal--first ParaOverride-6">Aaberg TM Jr, Rubsamen PE, Flynn HW Jr, Chang S, Mieler WF, Smiddy WE. &#173;Giant ret&#173;i&#173;nal tear as a complication of attempted removal of intravitreal lens fragments during cataract surgery. <span class="italic">Am J Ophthalmol.</span> 1997;124(2):222–226.</p>
			<p class="reference--journal--mid">Modi YS, Epstein A, Smiddy WE, Murray TG, Feuer W, Flynn HW&#160;Jr. Retained lens fragments &#173;after cataract surgery: outcomes of same-&#173;day versus &#173;later pars plana vitrectomy. <span class="italic">Am J </span><span class="italic">Ophthalmol.</span> 2013;156(3):454–459.</p>
			<p class="reference--journal--mid">Vanner EA, Stewart MW. Vitrectomy timing for retained lens fragments &#173;after surgery for age-&#173;related cataracts: a systematic review and meta-&#173;analysis. <span class="italic">Am J Ophthalmol.</span> 2011;152(3):<br />345–357.</p>
			<p class="h2 ParaOverride-11">Posteriorly Dislocated Intraocular Lenses</p>
			<p class="body-text--no-indent-">Posterior chamber intraocular lenses (PCIOLs) may become dislocated despite seemingly satisfactory capsular support at the time of the initial surgery. &#173;Factors to consider when placing a sulcus-&#173;fixated IOL include the presence of zonular dehiscence, total amount of anterior capsular support (eg, <span class="symbol">&gt;</span>180°), size of the eye, and haptic-&#173;to-&#173;haptic dia&#173;meter of the IOL. Foldable IOLs have a 12.5–13.0-mm haptic-&#173;to-&#173;haptic length. This length, which is frequently smaller than the sulcus-&#173;to-&#173;sulcus dia&#173;meter into which &#173;these haptics must fit, may contribute to postoperative subluxation or dislocation of the IOL. A flexible IOL may also become dislocated following Nd:YAG &#173;laser capsulotomy performed soon &#173;after cataract surgery. Late dislocation of the IOL (from several days to de&#173;cades &#173;after surgery) is less common but may occur as a result of trauma or spontaneous loss of zonular support in eyes with pseudoexfoliation syndrome. Treatment options in such cases include observation only, surgical repositioning, IOL exchange, or IOL removal.</p>
			<p class="body-text">In vitrectomy for posteriorly dislocated IOLs, all vitreous adhesions to the IOL are removed in order to minimize vitreous traction to the ret&#173;ina when the lens is manipulated back into the anterior chamber. The IOL may be placed into the ciliary sulcus provided &#173;there is adequate support. If capsular support is inadequate, the IOL may be fixated by suturing the haptics to the iris <span class="italic">(iris fixation)</span> or sclera <span class="italic">(scleral fixation)</span> or by placing the haptics into intrascleral tunnels <span class="italic">(intrascleral fixation).</span> Alternatively, the PCIOL can be removed through a limbal incision and exchanged for an anterior chamber IOL (ACIOL; Video 20-6).</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer011" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto"> <span class="QR-code-number">VIDEO 20-6</span> Vitrectomy for retrieval of posteriorly dislocated IOL.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer012" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source-recto">Courtesy of Colin&#160;A. McCannel, MD.</p>
			<p class="reference--non-journal--single ParaOverride-4">Smiddy WE, Flynn HW&#160;Jr. Managing retained lens fragments and dislocated posterior chamber IOLs &#173;after cataract surgery. <span class="italic">Focal Points: Clinical Modules for Ophthalmologists.</span> San Francisco: American Acad&#173;emy of Ophthalmology; 1996, module 7.</p>
			<p class="h2 ParaOverride-11">Cystoid Macular Edema</p>
			<p class="body-text--no-indent-">Cystoid macular edema (CME) that develops &#173;after anterior segment surgery usually resolves spontaneously. Treatment with corticosteroid and nonsteroidal anti-&#173;inflammatory eye drops is the first-&#173;line approach for patients with per&#173;sis&#173;tent CME. Periocular or intravitreal corticosteroids may be used in recalcitrant cases. Oral acetazolamide may also be useful in some cases. Pars plana vitrectomy with removal of obvious vitreous adhesions to anterior segment structures may promote resolution of CME and improve visual acuity in select cases (<span class="xref-figure">Fig&#160;20-10</span>). An IOL may require repositioning, exchange, or removal if it is deemed that the IOL is irritating the iris by chafing or capture.</p>
			<p class="h2">Suprachoroidal Hemorrhage</p>
			<p class="body-text--no-indent-">Suprachoroidal hemorrhage may occur during or &#173;after any form of intraocular surgery, particularly glaucoma surgery, in which large variations in IOP are commonplace. By definition, such hemorrhages accumulate in the supraciliary and suprachoroidal space, a potential space between the sclera and uvea that is modified by uveal adhesions and entries of vessels. Hemorrhages may be limited or massive and involve 1–4 quadrants. When ret&#173;i&#173;nal surfaces touch one another, dictated by scleral spur and the entries of the short posterior ciliary vessels and nerves, the choroidal hemorrhage is termed <span class="italic">appositional,</span> or “kissing.” &#173;These hemorrhages may be further classified as nonexpulsive or expulsive; the expulsive type involves extrusion of intraocular contents. Reported risk &#173;factors for suprachoroidal hemorrhage include</p>
			<ul>
				<li class="bullet-list-first ParaOverride-12">advanced age</li>
				<li class="bullet-list-mid">aphakia</li>
				<li class="bullet-list-mid">arteriosclerotic cardiovascular disease</li>
				<li class="bullet-list-mid">glaucoma</li>
				<li class="bullet-list-mid">hypertension</li>
				<li class="bullet-list-mid">intraoperative tachycardia</li>
				<li class="bullet-list-mid">myopia</li>
				<li class="bullet-list-last">Sturge-&#173;Weber–&#173;associated choroidal hemangiomas</li>
			</ul>
			<p class="body-text--no-indent-">Transient hypotony is a common feature of all incisional ocular surgery; in a small percentage of patients, it may be associated with suprachoroidal hemorrhage from rupture of the long or short posterior ciliary arteries.</p>
			<p class="body-text">Surgical management strategies are controversial. Most studies recommend immediate closure of ocular surgical incisions and removal of vitreous incarceration in the wound, if pos&#173;si&#173;ble; the primary goal is to prevent or limit expulsion. Successful intraoperative drainage of a suprachoroidal hemorrhage is rare, however, &#173;because the blood coagulates rapidly. Most surgeons recommend observation of suprachoroidal hemorrhages for 7–14&#160;days to allow some degree of liquefaction of the hemorrhage. Determining the timing of secondary surgical intervention is aided by B-&#173;scan ultrasound, through evaluation of echographic features of clot liquefaction. Indications for surgical drainage include recalcitrant pain, increased IOP, ret&#173;i&#173;nal detachment, and appositional choroidal detachments associated with ciliary body rotation and &#173;angle closure. Furthermore, prolonged IOP elevation in the presence of an anterior chamber hemorrhage (hyphema) increases the risk of corneal blood staining and is an indication for surgical intervention.</p>
			<p class="body-text">In surgical management of suprachoroidal hemorrhage, an anterior chamber infusion line is placed to maintain IOP (<span class="xref-figure">Video 20-7, Fig 20-11</span>). A full-&#173;thickness sclerotomy is then placed subjacent to the site of maximum accumulation of blood. &#173;After the suprachoroidal blood drains, pars plana vitrectomy may be performed. Appositional and closed-&#173;funnel suprachoroidal hemorrhage, prolonged elevation of IOP, and ret&#173;i&#173;nal detachment all portend a poor visual prognosis.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer013" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto"> <span class="QR-code-number">VIDEO 20-7</span> Drainage of suprachoroidal hemorrhage.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer014" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source-recto">Courtesy of Koen&#160;A. van Overdam, MD.</p>
			<p class="reference--journal--single ParaOverride-4">Scott IU, Flynn HW Jr, Schiffman J, Smiddy WE, Murray TG, Ehlies&#160;F. Visual acuity outcomes among patients with appositional suprachoroidal hemorrhage. <span class="italic">Ophthalmology.</span> 1997;104(12):2039–2046.</p>
			<p class="h2 ParaOverride-13">Needle Penetration of the Globe</p>
			<p class="body-text--no-indent-">&#173;Factors predisposing patients to needle penetration of the globe include</p>
			<ul>
				<li class="bullet-list-first">axial high myopia</li>
				<li class="bullet-list-mid">inexperience of the practitioner</li>
				<li class="bullet-list-mid">poor patient cooperation at the time of the injection</li>
				<li class="bullet-list-mid">posterior staphyloma</li>
				<li class="bullet-list-mid">previous scleral buckling surgery</li>
				<li class="bullet-list-last">scleromalacia</li>
			</ul>
			<p class="body-text">Management options vary with the severity of the intraocular damage. Often, blood obscures and surrounds the ret&#173;i&#173;nal penetration site, making &#173;laser treatment difficult. Observation or transscleral cryotherapy may be considered in such cases. When ret&#173;i&#173;nal detachment is pres&#173;ent, early vitrectomy with or without scleral buckling is often recommended. Posterior pole damage from needle extension into the macula or optic nerve is associated with a very poor visual prognosis (<span class="xref-figure">Fig&#160;20-12</span>).</p>
			</div>
			<p class="h1 ParaOverride-9">Rhegmatogenous Retinal Detachment Surgery</p>
			<div id="Chapt20_Top6">
			<p class="body-text--no-indent-">Rhegmatogenous ret&#173;i&#173;nal detachment occurs when a ret&#173;i&#173;nal break (or multiple breaks) allows ingress of fluid from the vitreous cavity into the subret&#173;i&#173;nal space. Breaks can be atrophic, often associated with lattice degeneration, or they may be tractional tears, related to vitreous traction on the ret&#173;ina and posterior vitreous detachment (PVD). The risk of rhegmatogenous ret&#173;i&#173;nal detachment (RRD) in other&#173;wise normal eyes is approximately 5&#160;new cases in 100,000 persons per year; lifetime risk is approximately 1&#160;in 300 persons. The most significant risk &#173;factors are high myopia, &#173;family history of ret&#173;i&#173;nal detachment, and fellow-&#173;eye ret&#173;i&#173;nal detachment. Pseudophakia is also an impor&#173;tant risk &#173;factor; the reported incidence &#173;after cataract surgery is less than 1% but increases over time (<span class="xref-figure">Fig&#160;20-13</span>). Patient characteristics that increase the risk of pseudophakic ret&#173;i&#173;nal detachment include younger age at the time of cataract extraction, male sex, and longer axial length. A surgical complication such as posterior capsular rupture with vitreous loss has been estimated to increase the risk of ret&#173;i&#173;nal detachment by as much as 20-&#173;fold.</p>
			<p class="body-text">Management options for RRD include <span class="italic">&#173;laser demarcation</span> of the detachment, <span class="italic">pneumatic retinopexy, scleral buckling procedure,</span> and <span class="italic">vitrectomy with or</span> <span class="italic">without scleral buckling.</span> Observation can be considered for selected patients with localized ret&#173;i&#173;nal detachment and no associated symptoms (subclinical ret&#173;i&#173;nal detachment).</p>
			<p class="body-text">Se&#173;lection of the treatment approach among the modalities available for ret&#173;i&#173;nal detachment is surgeon-&#173;dependent and remains a topic of debate among ret&#173;i&#173;nal surgeons. The precise configuration of the detachment, the location of the breaks, and the phakic&#160;status of the eye are all considered carefully before the method of treatment is determined.</p>
			<p class="reference--journal--first">Clark A, Morlet N, Ng JQ, Preen DB, Semmens JB. Risk for ret&#173;i&#173;nal detachment &#173;after phacoemulsification: a whole-&#173;population study of cataract surgery outcomes. <span class="italic">Arch Ophthalmol.</span> 2012;130(7):882–888.</p>
			<p class="reference--journal--last ParaOverride-7">Powell SK, Olson RJ. Incidence of ret&#173;i&#173;nal detachment &#173;after cataract surgery and neodymium: YAG &#173;laser capsulotomy. <span class="italic">J Cataract Refract Surg.</span> 1995;21(2):132–135.</p>
			<p class="h2 ParaOverride-14">Techniques for Surgical Repair of Ret&#173;i&#173;nal Detachments</p>
			<p class="body-text--no-indent-">&#173;There are 3 surgical techniques for eyes with primary uncomplicated rhegmatogenous ret&#173;i&#173;nal detachment: <span class="italic">pneumatic retinopexy, scleral buckling,</span> and <span class="italic">primary vitrectomy with or</span> <span class="italic">without scleral buckling.</span> The common goals of &#173;these procedures are to identify and treat all causative ret&#173;i&#173;nal breaks while supporting such breaks through external and internal tamponade as needed.</p>
			<p class="reference--journal--first ParaOverride-15">Kreissig I, ed. <span class="italic">Primary Ret&#173;i&#173;nal Detachment: Options for Repair.</span> Berlin: Springer-&#173;Verlag; 2005.</p>
			<p class="reference--journal--last ParaOverride-7">Campo RV, Sipperley JO, Sneed SR, et&#160;al. Pars plana vitrectomy without scleral buckle for pseudophakic ret&#173;i&#173;nal detachments. <span class="italic">Ophthalmology.</span> 1999;106(9):1811–1816.</p>
			<p class="h3">Pneumatic retinopexy</p>
			<p class="body-text--no-indent-">Pneumatic retinopexy closes ret&#173;i&#173;nal breaks by using an intraocular gas &#173;bubble for a sufficient time to allow the subret&#173;i&#173;nal fluid to reabsorb and a chorioret&#173;i&#173;nal adhesion to form around the causative break(s). The classic indications for pneumatic retinopexy include</p>
			<ul>
				<li class="bullet-list-first ParaOverride-12">confidence that all ret&#173;i&#173;nal breaks have been identified</li>
				<li class="bullet-list-mid">ret&#173;i&#173;nal breaks that are confined to the superior 8 clock-&#173;hours</li>
				<li class="bullet-list-mid">a single ret&#173;i&#173;nal break or multiple breaks within 1–2 clock-&#173;hours</li>
				<li class="bullet-list-mid">the absence of proliferative vitreoretinopathy (PVR) grade C or D</li>
				<li class="bullet-list-mid">a cooperative patient who can maintain proper positioning</li>
				<li class="bullet-list-last">clear media</li>
			</ul>
			<p class="body-text--no-indent-">With direct pneumatic occlusion of the causative ret&#173;i&#173;nal breaks in acute detachments, subret&#173;i&#173;nal fluid is often completely reabsorbed within 6–8 hours.</p>
			<p class="body-text">Transconjunctival cryopexy can be performed on the causative ret&#173;i&#173;nal breaks; alternatively, &#173;laser retinopexy may be performed &#173;after ret&#173;i&#173;nal apposition. A variety of intraocular gases (eg, air, SF<span class="subscript _idGenCharOverride-1">6</span>, C<span class="subscript _idGenCharOverride-1">3</span>F<span class="subscript _idGenCharOverride-1">8</span>) can be used for tamponade, and a concomitant anterior chamber paracentesis is generally required to normalize the elevated IOP that results from the gas injection. The patient must maintain a predetermined head posture to place the breaks in the least dependent position (<span class="xref-figure">Fig&#160;20-14</span>).</p>
			<p class="body-text">A prospective, multicenter, randomized clinical trial comparing pneumatic retinopexy with scleral buckling demonstrated successful ret&#173;i&#173;nal reattachment in 73% of patients who underwent pneumatic retinopexy and in 82% of &#173;those who received scleral buckle procedures; this difference was not statistically significant. Complications from pneumatic retinopexy include subret&#173;i&#173;nal gas migration, anterior chamber gas migration, endophthalmitis, cataract, and recurrent ret&#173;i&#173;nal detachment from the formation of new ret&#173;i&#173;nal breaks.</p>
			<p class="reference--journal--first">Gilca M, Duval R, Goodyear E, Olivier S, Cordahi&#160;G. &#173;Factors associated with outcomes of pneumatic retinopexy for rhegmatogenous ret&#173;i&#173;nal detachments: a retrospective review of 422 cases. <span class="italic">Ret&#173;i&#173;na.</span> 2014;34(4):693–699.</p>
			<p class="reference--journal--last ParaOverride-7">Tornambe PE, Hilton GF; The Ret&#173;i&#173;nal Detachment Study Group. Pneumatic retinopexy. A multicenter randomized controlled clinical trial comparing pneumatic retinopexy with scleral buckling. <span class="italic">Ophthalmology.</span> 1989;96(6):772–784.</p>
			<p class="h3 ParaOverride-3">Scleral buckling</p>
			<p class="body-text--no-indent-">Scleral buckling closes ret&#173;i&#173;nal breaks through external scleral indentation. Transscleral cryopexy is used to create a permanent adhesion between the ret&#173;ina and RPE at the sites of ret&#173;i&#173;nal breaks. The buckling material is then carefully positioned to support the causative breaks by scleral imbrication.</p>
			<p class="body-text">The surgeon chooses the scleral buckling technique (eg, encircling, segmental, or radial placement of the sponge, sutured vs scleral tunnels) according to the number and position of retinal breaks, eye size, and associated vitreoretinal findings (eg, lattice degeneration, vitreoretinal traction, aphakia), and individual preference and training (Video 20-8, Fig 20-15).</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer015" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto"> <span class="QR-code-number">VIDEO 20-8</span> Scleral buckle for rhegmatogenous ret&#173;i&#173;nal detachment.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer016" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source-recto">Courtesy of Colin&#160;A. McCannel, MD.</p>
			<p class="body-text">An increase in the IOP related to compression from the buckling effect may indicate the need for external drainage of the subret&#173;i&#173;nal fluid, anterior chamber paracentesis, or both. Chronic viscous subret&#173;i&#173;nal fluid, “fish-&#173;mouthing” of large ret&#173;i&#173;nal breaks, and bullous ret&#173;i&#173;nal detachments may necessitate treatment with intraocular gas tamponade, drainage, or both. Complications of scleral buckling include induced myopia, anterior ocular ischemia, diplopia, ptosis, orbital cellulitis, subret&#173;i&#173;nal hemorrhage from drainage, and ret&#173;i&#173;nal incarceration at the drainage site.</p>
			<p class="h3">Primary vitrectomy</p>
			<p class="body-text--no-indent-">Traction on focal areas of adhesion of the vitreous to the peripheral ret&#173;ina (frequently at the posterior vitreous base insertion) may cause ret&#173;i&#173;nal breaks, allowing intraocular fluid to migrate into the subret&#173;i&#173;nal space, which leads to ret&#173;i&#173;nal detachment. Consequently, the goals of primary vitrectomy are to remove cortical vitreous adherent to ret&#173;i&#173;nal breaks, directly drain the subret&#173;i&#173;nal fluid, tamponade the breaks (using air, gas, or silicone oil), and create chorioret&#173;i&#173;nal adhesions around each ret&#173;i&#173;nal break with endolaser photocoagulation or cryopexy.</p>
			<p class="body-text">In general, the 3-&#173;port vitrectomy technique is used, employing 20-&#173;gauge, 23-&#173;gauge, 25-&#173;gauge, or 27-&#173;gauge instruments. At the surgeon’s discretion, vitrectomy can be combined with a scleral buckle procedure. During vitrectomy, a complete posterior vitreous separation is ensured, and the peripheral cortical vitreous is carefully shaved &#173;toward the vitreous base to relieve traction on the ret&#173;i&#173;nal breaks (<span class="xref-figure">Video 20-9, Fig 20-16</span>). To drain the subret&#173;i&#173;nal fluid and achieve intraoperative ret&#173;i&#173;nal reattachment, the surgeon can use &#173;either an intentional drainage retinotomy or perfluorocarbon liquid technique. If PVR is pres&#173;ent, it may be necessary to peel the epiret&#173;i&#173;nal (and, less commonly, subret&#173;i&#173;nal) membranes to facilitate the ret&#173;i&#173;nal reattachment. For extensive PVR, a relaxing retinotomy or retinectomy may be required. Once the ret&#173;ina is flattened, chorioret&#173;i&#173;nal &#173;laser photocoagulation or cryopexy can be applied. Postoperative tamponade is generally provided by intraocular air or nonexpansile concentrations of SF<span class="subscript _idGenCharOverride-1">6</span> or C<span class="subscript _idGenCharOverride-1">3</span>F<span class="subscript _idGenCharOverride-1">8</span> gas, although in complex cases the use of silicone oil may be required. Complications of vitrectomy for ret&#173;i&#173;nal detachment include postvitrectomy nuclear sclerosis (in phakic eyes), glaucoma, PVR, and ret&#173;i&#173;nal redetachment.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer017" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"> <span class="QR-code-number">VIDEO 20-9</span> Vitrectomy for rhegmatogenous ret&#173;i&#173;nal detachment.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer018" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source">Courtesy of Colin&#160;A. McCannel, MD.</p>
			<p class="body-text">Complex ret&#173;i&#173;nal detachment includes &#173;giant ret&#173;i&#173;nal tears, recurrent ret&#173;i&#173;nal detachment, vitreous hemorrhage, and PVR. The surgeon must use pars plana vitrectomy techniques in order to address the common features of PVR, including proliferative membranes, ret&#173;i&#173;nal folds, and media opacities (see <span class="xref-local">Chapter&#160;16</span>). In the past, controversy surrounded the use of long-&#173;acting gas versus silicone oil in ret&#173;i&#173;nal tamponade for eyes with complex ret&#173;i&#173;nal detachment caused by advanced grades of PVR. This issue was addressed in the Silicone Study, a prospective, multicenter, randomized study, which concluded that tamponade with SF<span class="subscript _idGenCharOverride-1">6</span> was inferior to long-&#173;term tamponade with &#173;either C<span class="subscript _idGenCharOverride-1">3</span>F<span class="subscript _idGenCharOverride-1">8</span> or silicone oil. Differences in outcomes from the use of C<span class="subscript _idGenCharOverride-1">3</span>F<span class="subscript _idGenCharOverride-1">8</span> and silicone oil &#173;were statistically insignificant; however, patients treated with silicone oil experienced a lower rate of hypotony than &#173;those treated with C<span class="subscript _idGenCharOverride-1">3</span>F<span class="subscript _idGenCharOverride-1">8</span>.</p>
			<p class="reference--journal--first ParaOverride-6">Vitrectomy with silicone oil or sulfur hex&#173;a&#173;fluor&#173;ide gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study report 1. <span class="italic">Arch Ophthalmol.</span> 1992;110(6):770–779.</p>
			<p class="reference--journal--mid">Vitrectomy with silicone oil or perfluoropropane gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study report 2. <span class="italic">Arch Ophthalmol.</span> 1992;110(6):780–792.</p>
			<p class="h2 ParaOverride-16">Outcomes Following Ret&#173;i&#173;nal Reattachment Surgery</p>
			<p class="h3-h2">Anatomical reattachment</p>
			<p class="body-text--no-indent-">In the absence of PVR, the overall rate of primary anatomical reattachment with current techniques is 80%–90% for the primary surgery. The exact rate depends on technique and preoperative ocular findings. In patients with PVR or who have had previous reattachment surgeries, success rates are in the 70% range. However, rates for final reattachment, even if multiple procedures are required, are in the 90%–100% range. Ret&#173;i&#173;nal detachments caused by dialyses or small holes or that are associated with demarcation lines have a better prognosis. Aphakic and pseudophakic eyes have a slightly less favorable prognosis. Detachments caused by &#173;giant tears or that are associated with PVR, uveitis, choroidal detachments, or posterior breaks secondary to trauma have the worst prognosis for anatomical reattachment.</p>
			<p class="reference--non-journal--single ParaOverride-6">&#173;Sullivan&#160;P. Techniques of scleral buckling. In: Schachat AP, Wilkinson CP, Hinton DR, Sadda SR, Wiedemann P, eds. <span class="italic">Ryan’s</span> <span class="italic">Ret&#173;i&#173;na.</span> Vol 3. 6th&#160;ed. Philadelphia: Elsevier/Saunders; 2018.</p>
			<p class="h3">Postoperative visual acuity</p>
			<p class="body-text--no-indent-">The status of the macula—&#173;whether it was detached and for how long—is the primary presurgical determinant of postoperative visual acuity. If the macula was not detached (“macula-on” ret&#173;i&#173;nal detachment) and the ret&#173;i&#173;nal detachment is successfully repaired, restoration of preoperative visual acuity is usually expected. However, 10%–15% of &#173;these eyes do not return to preoperative visual acuity.</p>
			<p class="body-text">If the macula was detached preoperatively (“macula-&#173;off” ret&#173;i&#173;nal detachment), damage to—or degeneration of—&#173;photoreceptors may prevent good postoperative visual acuity. Only approximately one-&#173;third to one-&#173;half of eyes with a detached macula recover visual acuity to the level of 20/50 or better. Among patients with a macular detachment of less than 1 week’s duration, 75% &#173;will obtain a final visual acuity of 20/70 or better, as opposed to 50% with a macular detachment of a duration exceeding 7–10 days but shorter than 8 weeks.</p>
			<p class="body-text">In addition to photoreceptor damage from the detachment, &#173;factors associated with visual acuity deterioration or incomplete recovery following successful ret&#173;i&#173;nal reattachment surgery include irregular astigmatism, cataract progression, per&#173;sis&#173;tent subfoveal fluid, macular edema, or macular pucker. Intraoperative complications such as hemorrhage and preexisting ocular pathology may also limit visual recovery.</p>
			</div>
			<p class="h1">Complications of Pars Plana Vitrectomy</p>
			<div id="Chapt20_Top7">
			<p class="body-text--no-indent-">Nuclear sclerotic cataract is the most common complication of vitrectomy. Within 3–6&#160;months following vitrectomy, as many as 90% of phakic eyes in patients older than 50&#160;years may develop visually significant nuclear sclerotic cataract. Vitrectomy may also increase the long-&#173;term risk of open-&#173;angle glaucoma. Both cataract progression and glaucoma are speculated to be the result of increased oxygen tension in the eye &#173;after vitrectomy, which in turn results in oxidative damage to the lens and trabecular meshwork, respectively.</p>
			<p class="body-text">Other complications of pars plana vitrectomy include intraoperative ret&#173;i&#173;nal tears (approximately 1%–5%), postoperative detachment (approximately 1%–2%), retention of subret&#173;i&#173;nal perfluorocarbon liquid (when used), ret&#173;i&#173;nal and vitreous incarceration, endoph&#173;thalmitis (approximately 0.05%), suprachoroidal hemorrhage and recurrent vitreous hemorrhage (approximately less than 1%; up to 5% and higher in diabetics). Endophthalmitis &#173;after vitrectomy is more common in patients with diabetes mellitus and in eyes with retained intraocular foreign bodies. <span class="xref-table">&#173;Table&#160;20-2</span> lists the most common complications of pars plana vitrectomy.</p>
			<p class="reference--journal--first">Banker AS, Freeman WR, Kim JW, Munguia D, Azen SP; Vitrectomy for Macular Hole Study Group. Vision-&#173;threatening complications of surgery for full-&#173;thickness macular holes. <span class="italic">Ophth</span><span class="italic">almology.</span> 1997;104(9):1442–1453.</p>
			<p class="reference--journal--mid">Chang&#160;S. LXII Edward Jackson lecture: open &#173;angle glaucoma &#173;after vitrectomy. <span class="italic">Am J Ophthalmol.</span> 2006;141(6):1033–1043.</p>
			<p class="reference--journal--mid">Thompson JT. The role of patient age and intraocular gases in cataract progression following vitrectomy for macular holes and epiret&#173;i&#173;nal membranes. <span class="italic">Trans Am Ophthalmol Soc.</span> 2003;<br />101:485–498.</p>
			</div>
			<p class="h1">Intravitreal Injections</p>
			<div id="Chapt20_Top8">
			<p class="body-text--no-indent-">Intravitreal injections are the fastest-&#173;growing procedure in ophthalmology and in medicine in general (<span class="xref-figure">Video 20-10, Fig 20-17</span>). The most common indications for injections include AMD, diabetic retinopathy, and venous occlusive disease–&#173;associated macular edema. The most common injections are anti-&#173;angiogenic agents (eg, aflibercept, bevacizumab, and ranibizumab). Other intravitreal injections include ste&#173;roid preparations, including sustained delivery devices, antimicrobial medi&#173;cations, and many medi&#173;cations used in clinical &#173;trials that &#173;will likely be approved in the coming years. The number of injections performed in the United States, estimated from Medicare procedure codes, increased from fewer than 3000 per year in 1999 to an estimated 6.5 million in 2016. This number continues to increase as a result of the aging population, new medi&#173;cations becoming available, and an expanding list of indications.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer019" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto ParaOverride-10"> <span class="QR-code-number">VIDEO 20-10</span> Intravitreal injection of pharmacologic agent.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer020" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source-recto ParaOverride-17">Courtesy of Stephen&#160;J. Kim, MD.</p>
			<p class="body-text">Injections can be accomplished safely 3–4&#160;mm posterior to the limbus. Commonly used methods for anesthesia administration before intravitreal injections include pledgets or cotton-&#173;tip applicators soaked with anesthetic and held against the site of injection, application of topical (including viscous) formulations of anesthetic, and subconjunctival lidocaine injection. &#173;There is no consensus regarding the optimal method of anesthesia for patient comfort and reduced risk of infection.</p>
			<p class="body-text">Strict aseptic technique, including managing the eyelid to prevent contamination from the margin and lashes, is recommended. The application of povidone-&#173;iodine, 5%, to the ocular surface for at least 60–90 seconds prior to injection is widely considered beneficial. Antibiotic eyedrop use before or &#173;after injections is controversial and is not recommended in routine procedures, particularly given that repeat topical antibiotic application results in the development of resistant ocular flora.</p>
			<p class="body-text">Endophthalmitis remains the most feared complication resulting from an intravitreal injection; the reported incidence ranges from 0.02% to 0.2%. Although respiratory organisms could cause endophthalmitis (via contamination from respiratory droplets), the most common source of infection is presumed to be the patient’s own conjunctiva or eyelids. Therefore, potential mechanisms of infection include direct inoculation of ocular surface bacteria into the vitreous or subsequent entry through a wound track. Multiple studies have reported that <span class="italic">Streptococcus viridans,</span> a common component of oral flora, is a more frequent cause of endophthalmitis following intravitreal injections than &#173;after other intraocular procedures, presumably from contamination by respiratory droplets. Consequently, attention should be paid to efforts that reduce the risk of respiratory-&#173;droplet contamination such as minimizing talking of both the patient and provider and the use of face masks during the procedure. In addition, excessive manipulation of the eyelid margin should be avoided to limit expression of bacteria-&#173;laden secretions from the meibomian glands, and aggressive treatment of blepharitis prior to intravitreal injection should be considered for patients with severe disease.</p>
			<p class="body-text">Outbreaks of endophthalmitis from contaminated bevacizumab in the past have prompted periodic review of compounding pharmacy practices and accreditation status to reduce the risk of &#173;future outbreaks. To minimize patient risk when bilateral injections are performed, many prac&#173;ti&#173;tion&#173;ers have &#173;adopted a workflow in which dif&#173;fer&#173;ent lot numbers of compounded medi&#173;cations are used for each eye.</p>
			<p class="body-text">Other complications include the development of elevated intraocular pressure following intravitreal injections of anti-&#173;VEGF agents, or as a common adverse effect of ste&#173;roid injections. A complication unique to the dexamethasone sustained-&#173;release implant is severe corneal endothelial toxicity if the implant migrates into the anterior chamber. Such migration has been reported to be common in aphakic eyes, but it can also occur in pseudophakic eyes.</p>
			<p class="reference--journal--first ParaOverride-2">Khurana RN, Appa SN, McCannel CA, et&#160;al. Dexamethasone implant anterior chamber migration: risk &#173;factors, complications, and management strategies. <span class="italic">Ophthalmology.</span> 2014;121(1):<br />67–71.</p>
			<p class="reference--journal--mid">Kim SJ, Chomsky AS, Sternberg P&#160;Jr. Reducing the risk of endophthalmitis &#173;after intravitreous injection. <span class="italic">JAMA Ophthalmol.</span> 2013;131(5):674–675.</p>
			<p class="reference--journal--mid">Kim SJ, Toma HS. Antimicrobial re&#173;sis&#173;tance and ophthalmic antibiotics: 1-&#173;year results of a longitudinal controlled study of patients undergoing intravitreal injections. <span class="italic">Arch Ophthalmol.</span> 2011;129(9):1180–1188.</p>
			<p class="reference--journal--last">McCannel CA. Meta-&#173;analysis of endophthalmitis &#173;after intravitreal injection of anti-&#173;vascular endothelial growth &#173;factor agents: causative organisms and pos&#173;si&#173;ble prevention strategies. <span class="italic">Ret&#173;i&#173;na.</span> 2011;31(4):654–661.</p>
		</div>
		</div>
		<div id="_idContainer022" class="_idGenObjectStyleOverride-1">
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer025">
				<div id="_idContainer023" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/AAX-8493.jpg" alt="" />
				</div>
				<div id="_idContainer024" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-1</span> Epiretinal membrane (ERM). <span class="figure-caption-italic">Top row,</span> color fundus photographs of a normal right eye and a left eye with a macular ERM that shows distortion of the foveal architecture and retinal striae. <span class="figure-caption-italic">Bottom row,</span> corresponding optical coherence tomography (OCT) images confirm preretinal traction from the ERM, associated loss of foveal contour, and macular thickening in the left eye. Visual acuity was 20/50 in the left eye with central distortion. This patient was a candidate for pars plana vitrectomy surgery. <span class="figure-source-note">(Courtesy of Stephen J. Kim, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer028">
				<div id="_idContainer026" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00848.png" alt="" />
				</div>
				<div id="_idContainer027" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-2</span> OCT images of an ERM forming a pseudohole in a patient with visual distortion and reduced visual acuity (20/50). <span class="figure-caption-bold">A,</span>&#160;A preretinal membrane distorts the retinal contour and intraretinal edema. <span class="figure-caption-bold">B,</span> Image taken 2&#160;months after surgery shows continued restoration of normal macular contour and the absence of the preretinal membrane and traction; visual acuity had improved to 20/25. <span class="figure-source-note">(Courtesy of Edward F. Cherney, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer029" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer032">
				<div id="_idContainer030" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-3</span> Vitreomacular traction syndrome in a patient with visual acuity of 20/60 and mild ophthalmoscopic findings. OCT scan shows a partial posterior detachment with persistent hyaloidal insertion at the center of the macula. Note the elevated fovea with complete loss of contour and inner schisis cavity. Pars plana vitrectomy with membrane peeling led to an improved visual acuity of 20/25 and resolution of symptomatic distortion. <span class="figure-source-note">(Courtesy of Stephen J. Kim, MD.)</span></p>
				</div>
				<div id="_idContainer031" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/AAX-8496.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer035">
				<div id="_idContainer033" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/AAX-8497.jpg" alt="" />
				</div>
				<div id="_idContainer034" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-4</span> Idiopathic macular hole. <span class="figure-caption-italic">Left,</span> Color fundus photograph and corresponding OCT image of a patient with a full-thickness macular hole who had experienced reduced visual acuity (20/100) for 3&#160;months. <span class="figure-caption-italic">Right,</span> Postoperative color fundus photograph and OCT image of the same patient. After vitrectomy, membrane peeling, and fluid–gas exchange, the macular hole closed, visual acuity improved to 20/25, and normal foveal anatomy was restored. <span class="figure-source-note">(Courtesy of Stephen J. Kim, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer038">
				<div id="_idContainer036" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00239.png" alt="" />
				</div>
				<div id="_idContainer037" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-5</span> Fundus photographs of submacular hemorrhage in age-related macular degeneration (AMD). <span class="figure-caption-bold">A,</span>&#160;Patient had a submacular hemorrhage for 5&#160;days and counting-fingers vision. <span class="figure-caption-bold">B,</span>&#160;After vitrectomy with subretinal infusion of tissue plasminogen activator and pneumatic displacement, dry atrophic changes are apparent. Visual acuity improved to 20/100. <span class="figure-source-note">(Courtesy of Nancy M. Holekamp, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer041">
				<div id="_idContainer039" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00849.png" alt="" />
				</div>
				<div id="_idContainer040" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-6</span> Color fundus photograph montages of diabetic tractional retinal detachment. <span class="figure-caption-bold">A,</span>&#160;Fibrovascular proliferation and a contracted posterior hyaloid along the retinal arcade vessels and over the macula cause elevation and distortion of the retinal surface at the arcade vessels and in the temporal macula. <span class="figure-caption-bold">B,</span>&#160;After surgery, the macula and vessels are flattened. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer044">
				<div id="_idContainer042" class="Basic-Graphics-Frame _idGenObjectStyleOverride-2">
				</div>
				<div id="_idContainer043" class="Basic-Text-Frame">
					<p class="sidebar-title">CLINICAL TRIAL 20-1</p>
					<p class="sidebar-h1">Endophthalmitis Vitrectomy Study (EVS)</p>
					<p class="sidebar-text--no-indent-"><span class="sidebar-italic">Objective:</span> Evaluate the role of pars plana vitrectomy and intravenous antibiotics in management of postoperative bacterial endophthalmitis.</p>
					<p class="sidebar-text--no-indent- ParaOverride-19"><span class="sidebar-italic">Participants:</span> Patients with clinical signs and symptoms of bacterial en&#173;dophthalmitis in an eye &#173;after cataract surgery or lens implantation; onset of infection is within 6 weeks of surgery.</p>
					<p class="sidebar-text--no-indent- ParaOverride-19"><span class="sidebar-italic">Randomization:</span> Patients &#173;were randomly assigned to immediate pars plana vitrectomy or to immediate tap and inject. Patients &#173;were randomly assigned to receive systemic antibiotics or no systemic antibiotics and evaluated at regular intervals &#173;after treatment.</p>
					<p class="sidebar-text--no-indent- ParaOverride-19"><span class="sidebar-italic">Outcome mea&#173;sures:</span> Standardized visual acuity testing and media clarity.</p>
					<p class="sidebar-text--no-indent- ParaOverride-19"><span class="sidebar-italic">Outcomes:</span></p>
					<p class="sidebar-numbered-list-first">1.&#9;No difference in final visual acuity or media clarity &#173;whether or not systemic antibiotics (amikacin/ceftazidime) &#173;were employed.</p>
					<p class="sidebar-numbered-list-mid">2.&#9;No difference in outcomes between the 3-&#173;port pars plana vitrectomy group and the immediate tap/biopsy group for patients with better than light perception visual acuity at the study entry examination.</p>
					<p class="sidebar-numbered-list-mid">3.&#9;For patients with light perception visual acuity, much better results in the immediate pars plana vitrectomy group:</p>
					<p class="sidebar-numbered-list-sub-lettered-list">a.&#9;Three times more likely to achieve <span class="math">≥</span> 20/40 (33% vs 11%)</p>
					<p class="sidebar-numbered-list-sub-lettered-list">b.&#9;Two times more likely to achieve <span class="math">≥</span> 20/100 (56% vs 30%)</p>
					<p class="sidebar-numbered-list-sub-lettered-list ParaOverride-20">c.&#9;Less likely to incur <span class="symbol">&lt;</span> 5/200 (20% vs 47%)</p>
					<p class="sidebar-text--no-indent-"><span class="sidebar-italic">Clinical impact:</span> Study completed in 1995. Revolutionized treatment of post–&#173;cataract surgery endophthalmitis by making tap and inject an office procedure for most eyes.</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer047">
				<div id="_idContainer045" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00241.png" alt="" />
				</div>
				<div id="_idContainer046" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-7</span> Acute-onset endophthalmitis. <span class="figure-caption-bold">A,</span>&#160;Patient with marked epibulbar hyperemia, iritis, hypopyon, and endophthalmitis 5&#160;days after cataract surgery. <span class="figure-caption-bold">B,</span>&#160;After a needle tap of vitreous and injection of intravitreal antibiotics, the inflammation resolved and visual acuity improved to 20/30. <span class="figure-source-note">(Courtesy of Harry W. Flynn, Jr, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer050">
				<div id="_idContainer048" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00242.png" alt="" />
				</div>
				<div id="_idContainer049" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-8</span> Chronic (delayed-onset) postoperative endophthalmitis. <span class="figure-caption-bold">A,</span>&#160;Endophthalmitis in a patient with progressive intraocular inflammation 3 months after cataract surgery. <span class="figure-caption-bold">B,</span>&#160;Same patient after pars plana vitrectomy, capsulectomy, and injection of intravitreal antibiotics. Culture results confirmed a diagnosis of <span class="figure-caption-italic">Propionibacterium acnes</span> endophthalmitis. <span class="figure-source-note">(Courtesy of Harry W. Flynn, Jr, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer053">
				<div id="_idContainer051" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00243.png" alt="" />
				</div>
				<div id="_idContainer052" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-9</span> Bleb-associated endophthalmitis. <span class="figure-caption-bold">A,</span>&#160;Patient with endophthalmitis who had a sudden onset of decreased vision, redness, and pain 2&#160;years after glaucoma filtering surgery. <span class="figure-caption-bold">B,</span>&#160;Same patient after treatment with pars plana vitrectomy and injection of intravitreal antibi&#173;otics. <span class="figure-source-note">(Courtesy of Harry W. Flynn, Jr, MD.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer054" class="_idGenObjectStyleOverride-1">
			<table id="table001" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table _1-BCSC-table-title" colspan="3">
							<p class="table-title"><span class="table-number">&#173;Table&#160;20-1</span> General Recommendations for Management of Retained Lens Fragments</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-1" />
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-1">
							<p class="table-column-head">For the anterior segment surgeon</p>
						</td>
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-1" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Attempt retrieval of displaced lens fragments only if fragments are readily accessible.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Perform anterior vitrectomy as necessary to avoid vitreous prolapse into the wound.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Insert an intraocular lens if pos&#173;si&#173;ble.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Close the cataract wound with interrupted sutures.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Prescribe topical medi&#173;cations as needed.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Refer the patient to a vitreoret&#173;i&#173;nal con&#173;sul&#173;tant.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-2" />
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-2">
							<p class="table-column-head">For the vitreoret&#173;i&#173;nal surgeon</p>
						</td>
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-2" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Observe eyes with minimal inflammation and/or a small lens fragment.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Continue topical medi&#173;cations as needed.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Schedule vitrectomy</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-2">if inflammation or IOP is not controlled.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-2">if a nuclear fragment is pres&#173;ent.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Delay vitrectomy if necessary to allow clearing of corneal edema.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Perform maximal core vitrectomy before phacofragmentation.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Start with low fragmentation power (5%–10%) for more efficient removal of the nucleus.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Prepare for secondary intraocular lens insertion if necessary.</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table _7-BCSC-table-body-last-row" />
						<td class="Basic-Table _7-BCSC-table-body-last-row">
							<p class="table-indent-1">Examine the ret&#173;i&#173;nal periphery for ret&#173;i&#173;nal tears or ret&#173;i&#173;nal detachment.</p>
						</td>
						<td class="Basic-Table _7-BCSC-table-body-last-row" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table _8-BCSC-table-note" colspan="3">
							<p class="table-footnote">IOP <span class="symbol">=</span> intraocular pressure.</p>
							<p class="table-source-note">Modified with permission from Flynn HW Jr, Smiddy WE, Vilar NF. Management of retained lens fragments &#173;after cataract surgery. In: Saer JB, ed. <span class="table-italic">Vitreo-&#173;Retinal and Uveitis Update: Proceedings of the New Orleans Acad&#173;emy of Ophthalmology Symposium. </span>The Hague, Netherlands: Kugler; 1998:149, 150.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer057">
				<div id="_idContainer055" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00244.png" alt="" />
				</div>
				<div id="_idContainer056" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-10</span> Fundus photographs of pseudophakic cystoid macular edema (CME). <span class="figure-caption-bold">A,</span>&#160;Patient has nonresolving CME, vitreous strands adhering to the cataract wound, and a dislocated intraocular lens (IOL). <span class="figure-caption-bold">B,</span>&#160;Same patient after pars plana vitrectomy, removal of vitreous strands, repositioning of IOL, and periocular administration of corticosteroids. CME has markedly improved. <span class="figure-source-note">(Courtesy of Harry W. Flynn, Jr, MD.</span>)</p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer060">
				<div id="_idContainer058" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00245.png" alt="" />
				</div>
				<div id="_idContainer059" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-11</span> Schematics of suprachoroidal hemorrhage. <span class="figure-caption-bold">A,</span>&#160;Anterior infusion and simultaneous drainage of suprachoroidal hemorrhage through pars plana sclerotomy. <span class="figure-caption-bold">B,</span>&#160;Pars plana vitrectomy removes vitreous prolapse while drainage of suprachoroidal hemorrhage continues. <span class="figure-source-note">(Courtesy of Harry W. Flynn, Jr, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer063">
				<div id="_idContainer061" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00249.png" alt="" />
				</div>
				<div id="_idContainer062" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-12</span> Color fundus photographs show damage from needle penetration of the globe. <span class="figure-caption-bold">A,</span>&#160;Needle penetration of the globe caused multiple retinal breaks, including damage to the macula. <span class="figure-caption-bold">B,</span>&#160;After retinal detachment, treatment consisted of vitrectomy, fluid–gas exchange, and endolaser photocoagulation of retinal breaks. Retinal reattachment was achieved, but the patient’s visual acuity remained very poor. <span class="figure-source-note">(Courtesy of Harry W. Flynn, Jr, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer064" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer067">
				<div id="_idContainer065" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/ICS00103.jpg" alt="" />
				</div>
				<div id="_idContainer066" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-13</span> Color fundus photograph montage of a patient with symptomatic retinal detachment from a large superotemporal break after cataract surgery. <span class="figure-source-note">(Courtesy of Nancy M. Holekamp, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer070">
				<div id="_idContainer068" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00246.png" alt="" />
				</div>
				<div id="_idContainer069" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-14</span> Schematic of pneumatic retinopexy. <span class="figure-caption-bold">A,</span>&#160;A small, expansile gas bubble is injected into the vitreous cavity. <span class="figure-caption-bold">B,</span>&#160;The bubble enlarges. The patient is positioned so the gas bubble occludes the retinal break, allowing for resorption of subretinal fluid. <span class="figure-source-note">(Illustration by Dave Yates.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer073">
				<div id="_idContainer071" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00850.png" alt="" />
				</div>
				<div id="_idContainer072" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-15</span> Scleral buckle procedure. The conjunctiva is opened; the rectus muscles are isolated and tagged with a “0” silk suture. <span class="figure-caption-bold">A,</span>&#160;The eye is rotated so the sclera is exposed. Using calipers, the surgeon measures and marks the location for the anterior and posterior scleral pass for the radial mattress suture. <span class="figure-caption-bold">B,&#160;C,&#160;</span>The posterior scleral suture pass is accomplished. <span class="figure-caption-bold">D,&#160;E,</span>&#160;The encircling element, a 506 sponge, is passed, using forceps, under the suture and rectus muscle. <span class="figure-caption-bold">F,&#160;</span>The scleral buckle is fully installed; the tied-up radial mattress suture is shown with the knot rotated posteriorly. <span class="figure-source-note">(Courtesy of Colin A. McCannel, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer074" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer077">
				<div id="_idContainer075" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/KIN00248.png" alt="" />
				</div>
				<div id="_idContainer076" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-16</span> Vitrectomy schematic. <span class="figure-caption-bold">A,</span>&#160;Surgeon’s view of a 20-gauge, 3-port pars plana vitrectomy. <span class="figure-caption-bold">B,</span>&#160;A cross-sectional view shows an infusion cannula, endoillumination probe, and vitrectomy cutting probe. <span class="figure-source-note">(Illustration by Dave Yates.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer078" class="_idGenObjectStyleOverride-1">
			<table id="table002" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-9" />
					<col class="_idGenTableRowColumn-10" />
					<col class="_idGenTableRowColumn-11" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table _1-BCSC-table-title" colspan="3">
							<p class="table-title"><span class="table-number">&#173;Table&#160;20-2</span> Complications of Pars Plana Vitrectomy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-1" />
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-1">
							<p class="table-head">Complications commonly associated with pars plana vitrectomy</p>
						</td>
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-1" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-3" />
						<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-3">
							<p class="table-indent-1">Postoperative nuclear sclerotic cataract</p>
						</td>
						<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-3" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Long-&#173;term risk of open-&#173;angle glaucoma</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Intraoperative or postoperative ret&#173;i&#173;nal break</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Intraoperative or postoperative ret&#173;i&#173;nal detachment</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Intraoperative cataract</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Postoperative vitreous hemorrhage</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Postoperative massive fibrin exudation</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Postoperative anterior segment neovascularization</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Endophthalmitis</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Ret&#173;i&#173;nal phototoxicity</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-2" />
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-2">
							<p class="table-head">Complications associated with silicone oil</p>
						</td>
						<td class="Basic-Table _6-BCSC-table-body-head CellOverride-2" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Glaucoma</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1">Band keratopathy</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-4" />
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-5">
							<p class="table-indent-1">Corneal decompensation</p>
						</td>
						<td class="Basic-Table _7-BCSC-table-body-last-row CellOverride-4" />
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer081">
				<div id="_idContainer079" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="Operator_BCSC1819_S12_C20_p381-404_3P-web-resources/image/AAX-8524.jpg" alt="" />
				</div>
				<div id="_idContainer080" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 20-17</span> Intravitreal injection. The ocular surface was anesthetized with subconjunctival injection of lidocaine, 2%, in the inferotemporal quadrant. An eyelid speculum was inserted, and povidone-iodine, 5%, applied to the ocular surface. After 2&#160;minutes, povidone-&#173;iodine was reapplied over the injection site and—after proper hand placement and no talking—the injection was made approximately 4&#160;mm from the limbus. <span class="figure-source-note">(Courtesy of Stephen J. Kim, MD.)</span></p>
				</div>
			</div>
		</div>
	</body>
</html>
